Inhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe Purchases 26,963 Shares of Stock

Inhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe purchased 26,963 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was bought at an average price of $15.05 per share, for a total transaction of $405,793.15. Following the purchase, the chief executive officer now owns 692,511 shares in the company, valued at approximately $10,422,290.55. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Mark Lappe also recently made the following trade(s):

• On Monday, September 16th, Mark Lappe bought 13,037 shares of Inhibrx stock. The stock was purchased at an average cost of $17.13 per share, for a total transaction of $223,323.81.
• On Monday, September 9th, Mark Lappe acquired 9,500 shares of Inhibrx stock. The stock was purchased at an average cost of $15.21 per share, for a total transaction of $144,495.00.
• On Friday, September 6th, Mark Lappe purchased 26,000 shares of Inhibrx stock. The shares were acquired at an average cost of $15.29 per share, for a total transaction of $397,540.00.
• On Tuesday, September 3rd, Mark Lappe purchased 20,000 shares of Inhibrx stock. The stock was bought at an average price of $15.81 per share, with a total value of $316,200.00.
• On Thursday, August 29th, Mark Lappe bought 10,000 shares of Inhibrx stock. The shares were bought at an average price of $14.03 per share, with a total value of $140,300.00.

Inhibrx Stock Performance

NASDAQ INBX opened at $17.43 on Tuesday. Inhibrx, Inc. has a fifty-two week low of $10.80 and a fifty-two week high of $18.95. The business has a fifty day moving average price of $13.71 and a two-hundred day moving average price of $23.60.

Inhibrx (NASDAQ:INBX) last released its earnings results on Tuesday, August 13th. The company reported $125.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.60) by $129.08. The business had revenue of $0.10 million during the quarter. As a group, research analysts predict that Inhibrx, Inc. will post 87.5 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, JMP Securities initiated coverage on shares of Inhibrx in a research report on Tuesday, July 23rd. They set a “market perform” rating for the company.

Institutional Trading of Inhibrx

A number of hedge funds have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. grew its position in Inhibrx by 8.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 229,866 shares of the company’s stock worth $8,735,000 after acquiring an additional 17,762 shares during the last quarter. Quadrant Capital Group LLC bought a new position in Inhibrx in the 4th quarter valued at approximately $26,000. HCR Wealth Advisors bought a new stake in Inhibrx during the 4th quarter worth approximately $239,000. Campbell & CO Investment Adviser LLC acquired a new position in Inhibrx in the 4th quarter valued at approximately $894,000. Finally, Vestal Point Capital LP bought a new position in shares of Inhibrx during the fourth quarter valued at $58,140,000. Institutional investors and hedge funds own 82.46% of the company’s stock.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.